Acneiform adverse drug reactions appear weeks to months after starting a new drug. Unlike classic acne vulgaris, they have monomorphic inflammatory lesions, affect atypical places outside of seborrheic areas, and can occur at any age. A wide range of drugs can trigger them, with targeted oncology therapies such as epidermal growth factor receptor inhibitors carrying the highest risk. Recently, the incidence of these reactions has been increasing with januskinase inhibitors, used in inflammatory diseases. Symptomatic treatment is often sufficient instead of discontinuing the drug, especially if it is necessary for a serious disease. Close collaboration between dermatologists and prescribers is key to managing skin effects and maintaining optimal therapy.